Recent strategies for the use of paclitaxel in the treatment of urological malignancies

World Journal of Urology

Volumn 16, Issue 2, 1998, Pages 155-162

  Bokemeyer, C ^a   Hartmann, J T ^a   Kuczyk, M A ^a   Truss, M C ^a   Kollmannsberger, C ^a   Beyer, J ^a   Jonas, U ^a   Kanz, L ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; PACLITAXEL;

BLADDER TUMOR; HUMAN; MALE; PROSTATE TUMOR; REVIEW; TESTIS TUMOR;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; HUMANS; MALE; PACLITAXEL; PROSTATIC NEOPLASMS; TESTICULAR NEOPLASMS; URINARY BLADDER NEOPLASMS;

EID: 0032373235     PISSN: 07244983     EISSN: None     Source Type: Journal    
DOI: 10.1007/s003450050044     Document Type: Article

References (61)

1. Beyer J. Kramar A, Mandanas R, Linkesch W, Greinix A. Droz JP. Pico JL. Diehl A, Bokemeyer C, Schmoll HJ, Nichols CR, Einhorn L, Siegen W (1996) High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variables. J Clin Oncol 14: 2638-2645
2. Bokemeyer C, Schmoll HJ, Natt F. et al (1994) Preliminary results of a phase I/II trial of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer. J Cancer Res Clin Oncol 120: 754-757
3. Bokemeyer C, Beyer J. Rüther U, Harstrick A, Weibach L, Köhrmann U, Verbeek W, Schmoll HJ (1996) Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer. Ann Oncol 7: 31-34
4. Bokemeyer C, Hartmann JT, Kuczyk MA, Truss MC, Beyer J, Jonas U, Kanz L (1996) The role of paclitaxel in chemosensitive urological malignancies: current strategies in bladder cancer and testicular germ-cell tumors. World J Urol 14: 354-359
5. Burch PA, Richardson RL, Cha SS, Camoriano JK (1997) Combination paclitaxel and cisplatin is active in advanced urothelial carcinoma (UC) (abstract 1175). Proc Am Soc Clin Oncol 16: 329A
6. Calvo E, Aramendia JM, Garcia-Foncillas J, Lôpez-Picazo JM, Garcia-Rayo S, Martinez-Aguillo M, Brugarolas A (1997) Paclitaxel (T) combination chemotherapy in untreated and in resistant stage IV transitional cell carcinoma (TCC) of the urinary bladder: a retrospective study (abstract 1178). Proc Am Soc Clin Oncol 16: 330A
7. Caty A. Oudard S, Humblet Y, Beauduin M, Sue E, Gil T, Piccart M, Rolland F, Fumoleau P, Bugat R, Houyau P, Monnier A, Sun X, Montcuquet P, Breza J, Novak J, Favreau E, Tresca P, Chopin D (1997) Phase II study of vinorelbine in patients with hormone refractory prostate cancer (abstract 1106). Proc Am Soc Clin Oncol 16: 311A
8. Chao CCK, Lee YI, Chen PW, et al (1991) Enhanced host cell reactivation of damaged plasmid DNA in HeLA cells resistant to cw-diamminedichloroplatinum (II). Cancer Res 51: 601-605
9. Chou TC, Motzer RJ, Tong Y, et al (1994) Computerized quantitation of synergy of various drugs against teratocarcinoma cells in vitro: a rational approach to clinical protocol design (abstract 1520). Proc Am Assoc Cancer Res 35: 254
10. Christou A, Roth B, Fox S, Williams S, Nichsol C, Loehrer P, Buday M, Einhorn L (1996) Phase II trial of paclitaxel in refractory germ cell neoplasms (abstract 632). Proc Am Soc Clin Oncol 15: 249
11. Crawford ED, Saiers JH, Baker LH, et al (1991) Gallium nitrate in advanced bladder carcinoma: Southwest Oncology Group study. Urology 38: 355-357
12. DeLena M, Gridelli C. Lorusso V, Amadori D, Antimi M, Luporini G, Pollera C, Olivia C (1996) Gemcitabine activity (objective responses and symptom improvement) in resistant stage IV bladder cancer (abstract 622). Proc Am Soc Clin Oncol 15: 246
13. Dreicer R, Gustin D, See WA. Williams RD (1996) Paclitaxel in advanced urothelial carcinoma: its role in patients with renal insufficiency and as salvage therapy (abstract 607). Proc Am Soc Clin Oncol 15: 242
14. Edelman MJ, Meyers F, Houston J, Lauder I, Davis UC, Sacramento CA, Sacramento VA (1997) Phase I trial of paclitaxel, carboplatin and methotrexate (MTX) with filgrastim (G-CSF) and leucovorin in advanced transitional cell carcinoma (TCC) (abstract 1186). Proc Am Soc Clin Oncol 16: 332A
15. Einhorn LH (1990) Treatment of testicular cancer: a new and improved model. J Clin Oncol 8: 1777-1781
16. Gabrilove JL, Jakubowski A, Scher H, et al (1988) Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med 318: 1414-1422
17. Gerl A, Wilmanns W (1996) Antitumor activity of paclitaxel after failure of high-dose chemotherapy in a patient with late relapse of a non-seminomatous germ cell tumor. Anticancer Drugs 7: 716-718
18. Harker WO, Meyers JF. Freiha FS, et al (1985) Cisplatin, methotrexate. and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study. J Clin Oncol 3: 1463-1470
19. Herr H W, Scher HI (1994) Neoadjuvant chemotherapy and partial cystectomy for invasive bladder cancer. J Clin Oncol 12: 975-980
20. Hill BT, Shellard SA, Whelan RDH, et al (1992) Deficient removal of the major platinum-DNA intrastrand cross-links in the sequences pGpG and pApG appears characteristic of testicular teratoma cell lines derived from tumours from untreated patients and may account for their sensitivity to cisplatin (abstract 221). Proc Am Soc Clin Oncol 11: 100
21. Hillcoat BL, Raghavan D, Matthews J, et al (1989) A randomized trial of cisplatin versus cisplatin plus methotrexate in advanced cancer of the urothelial tract. J Clin Oncol 7: 706-709
22. Hudes GR. Nathan F, Khater C. et al (1997) Phase II trial of 96-hour paclitaxel plus oral estromastine phosphate in metastatic hormone-refractory prostate cancer. J Clin Oncol 15: 3156-3163
23. Kaufman DS, Shipley WU, Griffin PP, et al (1993) Selective bladder preservation by combination treatment of invasive bladder cancer. N EnglJ Med 329: 1377-1382
24. Kohn EC, Sarosy G. Bicher A. et al (1994) Dose-intense taxol: high response rate in patients with platinum-resistant recurrent ovarian cancer. J Natl Cancer Inst 86: 18-24
25. McCaffrey JA, Hilton S, Mazumdar M, Spicer J, Meegan G, Kelly WK. Herr H, Sheinfeld J, Scher HI, Bajorin DF (1997) A phase II trial of ifosfamide. paclitaxel and cisplatin (ITP) in patients (pts) with transitional cell carcinoma (TCC) (abstract 1154). Proc Am Soc Clin Oncol 16: 324A
26. McGuire WP. Rowinsky EK. Rosenshein NB, et al (1989) Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 111: 273-279
27. McLaren B, Gallagher CJ. Mason M, Melesi G, Oliver RTD (1997) Paclitaxel, vinblastine, cisplatin (PVC) in patients with advanced transitional cell cancer (TCC) (abstract 1205). Proc Am Soc Clin Oncol 16: 337A
28. Moore MJ, Tannock F, Ernst DS, et al (1997) Gemcitabine: A promising new agent in the treatment of advanced urothelial cancer. J Clin Oncol 15: 3441-3445
29. Morant R. Ackermann D, Trinkler F, Schmid HP. Maibach R, Bernhard J, Hanselmann S. Bauer J, Barbu M, Hering F. for the Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland (1997) Gemcitabine in hormone refractory metastatic prostatic carcinoma - a phase II study of the SAKK (abstract 1109). Proc Am Soc Clin Oncol 16: 311A
30. Motzer RJ, Bajorin DF, Schwartz LH, Hutter HS, Bosl GJ, Scher HI. Lyn P. Fischer P (1994) Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors. J Clin Oncol 12: 2277-2283
31. Motzer RJ, Chou TC, Schwartz LH. Bosl GJ, Bajorin DF, Hutter H (1995) Paclitaxel in germ cell cancer. Semin Oncol 22 [Suppl 6]: 12-15
32. Motzer RJ (1997) Paclitaxel in salvage therapy for germ cell Tumors. Sem Oncol 24(Suppl 15): pp S 15-83-S15-85
33. Murphy BA, Johnson DR, Smith J, Koch M, DeVore R, Blanke C, Johnson DH (1996) Phase II trial of paclitaxel (P) and cisplatin (C) for metastatic or locally unresectable urothelial cancer (abstract 617). Proc Am Soc Clin Oncol 15: 245
34. Nichols C, Tricot G. Williams S, et al (1989) Dose-intensive chemotherapy in refractory germ cell cancer: a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation. J Clin Oncol 7: 932-939
35. Niell HB. Rangel C. Miller A, et al (1993) The activity of antimicrotubular agents in human bladder tumor cell lines (abstract). Proc Am Assoc Cancer Res 34: 202
36. Partyka S, Hutchinson L, Amato R (1996) Preliminary results of taxol/cisplatin chemotherapy in patients with refractory or relapsed nonseminomatous germ cell tumor (abstract 1161). Proc Am Assoc Cancer Res 37: 169
37. Pereboom E, Klein E, Olencki T. Connell C. Aaron R, Pratt S. Bukowski M (1996) Phase I trial of paclitaxel and estramustine in hormone refractory prostate cancer (HRPC) (abstract 690). Proc Am Soc Clin Oncol 15: 263
38. Peereboom DM, Wood L, Connell C, Spisak J. Smith D, Liebwohl D. Bukowski RM (1997) Phase II trial of oral BMS-182751 (JM-216) in hormone refractory prostate cancer (HRPC) (abstract 1210). Proc Am Soc Clin Oncol 16: 339A
39. Pollera CF. Ceribelli A, Crecco M. Calabresi F (1994) Weekly gemcitabine in advanced bladder cancer: a preliminary report from a phase I study. Ann Oncol 5: 182-184
40. Redman B, Hussain M, Smith D. Mertens W. Flaherty L (1997) Phase II evaluation of paclitaxel and carboplatin in advanced urothelial cancer (abstract 1157). Proc Am Soc Clin Oncol 16: 325A
41. Reichman BS, Seidman AD, Crown JP, et al (1993) Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol 83: 1797-1805
42. Roth BJ, Bajorin DF (1995) Advanced bladder cancer: the need to identify new agents in the post-M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) world. J Urol 153: 894-900
43. Roth BJ. Yeap BY. Wilding G, et al (1993) Taxol in advanced hormone-refractory carcinoma of the prostate. A phase II trial of the Eastern Cooperative Oncology Group. Cancer 72: 2457-2460
44. Roth B, Dreicer R. Einhorn LH. Neuber D. Johnson DH. Smith JL, Hudes GR. Schultz M, Loehrer PJ (1994) Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group. J Clin Oncol 12: 2264-2270
45. Roth BJ. Finch DE. Birhle R, Rowland RG, Foster RF. Collins M. Fox S. Williams SD (1997) A phase II trial of ifosfamide + paclitaxel (IT) in advanced transitional cell carcinoma of the urothelium (abstract 1156). Proc ASCO 1997. 16: 324A
46. Rowinsky EK. Gilbert MR, McGuire WP. et al (1991) Sequences of taxol and cisplatin: a phase I and pharmacologie study. J Clin Oncol 9: 1692-1703
47. Rowinsky EK. Eisenhauer EA. Chaudry V. et al (1993) Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol 4 [suppl 3]: 1-15
48. Scher HI, Norton L (1992) Chemotherapy for urothelial tract malignancies. Semin Surg Oncol 8: 316-341
49. Schiff PB, Fant J, Horwitz SB (1979) Promotion of microtubule assembly in vitro by taxol. Nature 277: 655-667
50. Schnack B, Grbovic M. Brodowicz T. Wiltschke C. Marberger M, Zielinski CC (1997) High effectivity of a combination of Taxol with carboplatin in the treatment of metastatic urothelial cancer, (abstract 1159) Proc Am Soc Clin Oncol 16: 325A
51. Seidman AD, Scher HI, Gabrilove JL. et al (1993) Dose-intensification of MVAC with recombinant granulocyte colonystimulating factor as initial therapy in advanced urothelial cancer. J Clin Oncol 11: 408-414
52. Siegert W, Beyer J, Strohscheer I. Baurmann H, Oettle H. Zingsem J. Zimmermann R. Bokemeyer C. Schmoll HJ. Huhn D (1994) High-dose treatment with carboplatin, etoposide and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase MI study. J Clin Oncol 12: 1223-1231
53. Slovin SF, Kelly WK, Cohen R. Cooper M. Malone T. Weingard K, Waksal H, Falcey J, Mendelsohn J, Scher HI (1997) Epidermal growth factor receptor (EGFr) monoclonal antibody (MoAb) C225 and doxorubicin (DOC) in androgen-independent (AI) prostate cancer (PC): results of a phase Ib/IIa study (abstract 1108). Proc Am Soc Clin Oncol 16: 311A
54. Smith DC. Esper PS, Todd RF III, Pienta KJ (1997) Paclitaxel. estramustine. and etoposide in patients with hormone refractory prostate cancer (HRPC): a phase II trial (abstract 1105). Proc Am Soc Clin Oncol 16: 310A
55. Sobecks RM, Stadier WM, Daugherty CK, Ratain MJ, Vogelzang NJ (1997) Vinorelbine (V) and paclitaxel (P) in relapsed metastatic bladder carcinoma (BC) (abstract 1230). Proc Am Soc Clin Oncol 16: 344A
56. Sternberg CN, Yagoda A, Scher HI, et al (1989) Methotrexate. vinblastine, doxorubicin and cisplatin for advanced transitional cell carcinoma of the urothelium: efficacy and patterns of response and relapse. Cancer 64: 2448-2458
57. Tu S, Hossan E, Amato R, Kilbourn R. Logothetis CJ (1995) Paclitaxel, cisplatin and methotrexate combination therapy is active in the treatment of refractory urothelial malignancies. J Urol 154: 1719-1722
58. Tu S, Pagliaro L, Kibourn R, Banks M, Bugazia N, Finn L, Eilerhorst J. Amato R, Millikan R, Madden T, Newman R, Logothetis CJ (1997) Suramin (SUR) combined with Adria-mycin (ADR) in the treatment of patients (pts) with advanced androgen-independent prostate carcinoma (AIPCA) (abstract 1239). Proc Am Soc Clin Oncol 16: 347 A
59. Vaughn DJ, Malkowicz SB, Zoltiek B, Ramchandani P. Tonkonow B, Fox K, Armstead B. Wein A (1996) Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: a well-tolerated outpatient regimen (abstract 597). Proc Am Soc Clin Oncol 15: 240
60. Vaughn DJ. Malkowicz SB. Zoltiek B. et al (1998) Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: An active and tolerable outpatient regimen. J Clin Oncol 16: 255-260
61. Wu N, Mirande K, Samuelson E, Kies M, Rossi D. Kozlowski J, Volini L. Kuzel TM (1997) Phase 1 trial of estramustine (EMT) and 3-hour infusional paclitaxel (TAX) for the treatment of hormone refractory prostate cancer (HRPC) (abstract 1245). Proc Am Soc Clin Oncol 16: 348A